论文部分内容阅读
目的观察和探讨纳洛酮联合门冬氨酸鸟氨酸治疗急性肝性脑病的临床疗效。方法选择于2013年1月~2015年1月我院收治的患有急性脑肝病的患者64例作为研究对象,随机分为两组,观察组和对照组,每组32例患者。观察组患者除采用常规治疗外,采用纳洛酮联合门冬氨酸鸟氨酸治疗。对照组患者在常规治疗基础上,采用纳洛酮治疗,观察对比两组患者的临床疗效,患者的血氨、ALT及TBIL以及神智转清醒时间。结果观察组的临床有效率为87.5%,对照组为65.625%,观察组的临床有效率显著优于对照组,并且具有显著性差异(P<0.05)。观察组患者的血氨、ALT及TBIL以及神智转清醒时间的时间显著低于对照组,并且具有显著性差异(P<0.05)。结论在对急性肝性脑病常规治疗基础上,纳洛酮联合门冬氨酸鸟氨酸治疗急性肝性脑病的临床效果显著,值得临床推广应用。
Objective To observe and explore the clinical efficacy of naloxone combined with aspartate ornithine in the treatment of acute hepatic encephalopathy. Methods From January 2013 to January 2015, 64 patients with acute cerebral hepatopathy admitted to our hospital were randomly divided into two groups: observation group and control group, with 32 patients in each group. Patients in the observation group were treated with naloxone combined with aspartate ornithine except conventional treatment. Patients in the control group were treated with naloxone on the basis of conventional treatment. The clinical efficacy, blood ammonia, ALT and TBIL, and the time of recuperation of the mind were observed and compared between the two groups. Results The clinical effective rate was 87.5% in the observation group and 65.625% in the control group. The clinical effective rate in the observation group was significantly better than that in the control group, with significant difference (P <0.05). The time of blood ammonia, ALT and TBIL, and the time to re-awake in the observation group were significantly lower than those in the control group, with significant difference (P <0.05). Conclusion Based on the routine treatment of acute hepatic encephalopathy, the clinical effect of naloxone combined with aspartate ornithine in the treatment of acute hepatic encephalopathy is significant and worthy of clinical application.